Nordic Life Science
Pharma
Latest Pharma News
The company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology. Removing the need for animal testing and
The Umeåbased startup company has been granted 2.2 million EUR from EU Horizon 2020, the EU framework program for research and development. The grant will go to Lipum’s ongoing development of a
Nordic Life Science asked some of the exhibitors at NLSDays about their experiences from the event. This time we spoke to Citoxlab and theit latest acquisition, Solvo Biotechnology. Have you
Nordic Life Science asked one of the exhibitors at NLSDays, MLM Medical Labs, about their experiences from the event. Could you tell me about your company? “We are a Central
The board of directors of the company have decided to shift strategic focus in the company’s product pipeline to biosimilars. As Xbrane’s leading biosimilar Xlucane (ranibizumab (Lucentis) biosimilar) moves into the
AstraZeneca and its partner Amgen have announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype,
Clinical trials
The first patient has been dosed in a Phase 2 study evaluating the combination therapy of the company’s cancer immunotherapy,
The company announces results from their BORA Phase III extension trial evaluating the long-term safety and efficacy of Fasenra (benralizumab) as an
Moberg Pharma has completed the recruitment of 365 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study
Ozempic consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke
Professor Jan Nilsson’s research team at Lund University has received an additional DKK 1,000,000 funding from the Novo Nordisk Foundation
AstraZeneca and MedImmune have announced new results from their TULIP 1 Phase III trial for anifrolumab in adult patients with
AstraZeneca has announced results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe
The Swedish company has announced the results of a preclinical study confirming the potential for its NanoZolid technology for use
The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and
The company announces results from its extension study of its Phase 2 study investigating the safety and immune responses of
The company begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the first
The first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301,
The company has reported positive results from a preclinical study in the field of acute kidney injury (AKI). The primary
Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo at the 23rd Congress of The European Hematology
AstraZeneca and Eli Lilly and Company are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase
Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited.
Pharma articles
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years. Few companies can take the hit of investing hundreds
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
Hans Lennernäs, professor in biopharmaceutics at Uppsala University, has extensive experience in developing drug delivery methods. NLS asked him about his research and ongoing activities in the field. He spoke
Much effort is being made to develop new medicines for diabetes and recent findings indicate the potential for new and improved pharmaceuticals. Diabetes is one of the largest global diseases
Profiles in Pharma
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development
Sirpa Jalkanen is a professor in the Academy of Finland, board member of Orion, and cofounder with her husband, Markku
Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula. While doing research for
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments